pharma · Vitiligo · Erythropoietic Protoporphyria (EPP)
CLINUVEL PHARMACEUTICALS
Clinuvel Europe Limited
Clinuvel Europe is a pharma organization headquartered in GB. Primary therapeutic focus areas include Vitiligo, Erythropoietic Protoporphyria (EPP), Parkinson's Disease, Arterial Ischaemic Stroke (AIS). NovaPharmaNews li
Melbourne, AU HQ
2001 Founded
83 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Melbourne, AU
- Founded
- 2001
- Employees
- 83
- Programs
- 5
- Drugs
- 3
- Patents
- 0
PRENUMBRA
Phase 2 · small molecule · Parkinson's Disease
PRENUMBRA for Parkinson's Disease is a Phase 2 program (small_molecule) at Clinuvel Europe Limited with 1 ClinicalTrials.gov record(s).
Internal code CUV901
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Clinuvel Europe Limited
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Parkinson's Disease
- Status
- active
- Trials
- 1